NCT01956084 - Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma | Biotech Hunter

Enrollment

10

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

November 19, 2017

Study Completion Date

October 15, 2019

Conditions

Hodgkin DiseaseNon Hodgkin LymphomaLymphoepitheliomaSevere Chronic Active EBV Infection Syndrome (SCAEBV)Leiomyosarcoma

Interventions

DRUG

LMP1/2 CTLs (Group A)

"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"

DRUG

LMP1/2 CTLs (Group B)

"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"

Trial Locations (1)

20010

Childrens National Medical Center, Washington D.C.